WO2001027080A3 - In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren - Google Patents

In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren Download PDF

Info

Publication number
WO2001027080A3
WO2001027080A3 PCT/EP2000/009847 EP0009847W WO0127080A3 WO 2001027080 A3 WO2001027080 A3 WO 2001027080A3 EP 0009847 W EP0009847 W EP 0009847W WO 0127080 A3 WO0127080 A3 WO 0127080A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclin
kinase
substituted indolinones
cdk complex
complex inhibitors
Prior art date
Application number
PCT/EP2000/009847
Other languages
English (en)
French (fr)
Other versions
WO2001027080A2 (de
Inventor
Gerald Juergen Roth
Armin Heckel
Rainer Walter
Van Jacobus Meel
Norbert Redemann
Gisela Schnapp
Ulrike Tontsch-Grunt
Walter Spevak
Original Assignee
Boehringer Ingelheim Pharma
Gerald Juergen Roth
Armin Heckel
Rainer Walter
Van Jacobus Meel
Norbert Redemann
Gisela Schnapp
Tontsch Grunt Ulrike
Walter Spevak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Gerald Juergen Roth, Armin Heckel, Rainer Walter, Van Jacobus Meel, Norbert Redemann, Gisela Schnapp, Tontsch Grunt Ulrike, Walter Spevak filed Critical Boehringer Ingelheim Pharma
Priority to AU76631/00A priority Critical patent/AU7663100A/en
Priority to EP00966136A priority patent/EP1224169A2/de
Publication of WO2001027080A2 publication Critical patent/WO2001027080A2/de
Publication of WO2001027080A3 publication Critical patent/WO2001027080A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft in 5-Stellung substituierte Indolinone der allgemeinen Formel (I), in der R1 bis R5 und X wie im Anspruch 1 definiert sind, deren Isomere und deren Salze, insbesondere deren physiologisch verträgliche Salze, welche wertvolle pharmakologische Eigenschaften aufweisen, insbesondere eine inhibierende Wirkung auf verschiedene Kinasen und Cyclin/CDK-Komplexe, auf Rezeptortyrosinkinasen sowie auf die Proliferation von Tumorzellen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung.
PCT/EP2000/009847 1999-10-13 2000-10-07 In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren WO2001027080A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU76631/00A AU7663100A (en) 1999-10-13 2000-10-07 Production of 5-substituted indolinones and use thereof as medicaments
EP00966136A EP1224169A2 (de) 1999-10-13 2000-10-07 In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin/cdk-komplexe inhibitoren

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19949209A DE19949209A1 (de) 1999-10-13 1999-10-13 In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19949209.3 1999-10-13

Publications (2)

Publication Number Publication Date
WO2001027080A2 WO2001027080A2 (de) 2001-04-19
WO2001027080A3 true WO2001027080A3 (de) 2001-11-22

Family

ID=7925398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009847 WO2001027080A2 (de) 1999-10-13 2000-10-07 In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren

Country Status (6)

Country Link
EP (1) EP1224169A2 (de)
AR (1) AR026037A1 (de)
AU (1) AU7663100A (de)
CO (1) CO5261507A1 (de)
DE (1) DE19949209A1 (de)
WO (1) WO2001027080A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
IL162203A0 (en) 2001-12-27 2005-11-20 Theravance Inc Indolinone derivatives useful as protein inase inhibitors
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE102004012068A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue alkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
DE102004012070A1 (de) 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CA2646638A1 (en) 2006-04-24 2007-11-01 Boehringer Ingelheim International Gmbh 3- (aminomethyliden) 2-indolinone derivatives and their use as cell proliferation inhibitors
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
PE20211054A1 (es) * 2018-10-05 2021-06-07 Ichnos Sciences S A Compuestos de indolinona para uso como inhibidores de map4k1
CN111285872B (zh) * 2018-12-06 2022-05-17 北京志健金瑞生物医药科技有限公司 吲哚-2-酮衍生物及其制备方法与用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0104860A1 (de) * 1982-09-20 1984-04-04 Pfizer Inc. Psychotherapeutische Wirkstoffe auf Basis von 1-Phenyl-2(1H,3H)-indolonen
US5886020A (en) * 1995-06-07 1999-03-23 Sugen, Inc. 3-(4'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0104860A1 (de) * 1982-09-20 1984-04-04 Pfizer Inc. Psychotherapeutische Wirkstoffe auf Basis von 1-Phenyl-2(1H,3H)-indolonen
US5886020A (en) * 1995-06-07 1999-03-23 Sugen, Inc. 3-(4'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GOLOVKO, T. V. ET AL: "Synthesis and pharmacological activity of 3-(aminomethylene)-2- indolinone derivatives", XP002170073, retrieved from STN Database accession no. 121:300712 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SESHADRI, S. ET AL: "Application of the Vilsmeier-Haack reaction to lactams. II. Reaction of substituted formanilide/phosphorus oxychloride complex on oxindole and other lactams", XP002170074, retrieved from STN Database accession no. 71:112732 *
INDIAN J. CHEM. (1969), 7(7), 667-71 *
KHIM.-FARM. ZH. (1994), 28(4), 22-6 *

Also Published As

Publication number Publication date
EP1224169A2 (de) 2002-07-24
AU7663100A (en) 2001-04-23
DE19949209A1 (de) 2001-04-19
CO5261507A1 (es) 2003-03-31
AR026037A1 (es) 2002-12-26
WO2001027080A2 (de) 2001-04-19

Similar Documents

Publication Publication Date Title
MY127956A (en) Substituted indolines which inhibit receptor tyrosine kinases
MY122357A (en) Indolinones having kinase inhibitory activity
WO2001027080A3 (de) In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren
WO1999057117A3 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
YU73900A (sh) Supstituisani indolinoni, njihovo pripremanje i njihova primena kao lekova
LUC00197I1 (de)
WO2004026829A3 (de) Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren
IL158975A0 (en) 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
BG105893A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
WO2006021881A3 (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MX2007003104A (es) Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.
AU3804500A (en) 2-amino-6-anilino-purines and their use as medicaments
DK1115704T3 (da) Substituerede indolinoner med inhiberende virkning for forskellige kinaser og cyclin/CDK komplekser
MXPA03010810A (es) Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos.
WO2002083667A3 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
MXPA05012592A (es) Nuevas piridopirazinas y uso de las mismas como inhibidores de cinasa.
CA2492804A1 (en) Novel inhibitors of kinases
CA2399358A1 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
AR025389A1 (es) Indolinonas sustituidas, su preparacion y su empleo como medicamentos
CA2367704A1 (en) Pyrazolobenzodiazepines as cdk2 inhibitors
TW200604169A (en) New cycloalkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments
WO2002014281A8 (en) Pyridine derivatives as inhibitors of p38
BR0208900A (pt) Indolinas substituìdas na posição 6 e seu uso como inibidores de cinase
RS20050047A (en) Indoline derivatives substituted in position 6,production and use thereof as medicaments
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000966136

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000966136

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000966136

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)